# Spermiogram Assessment in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis

> **NCT02431429** · — · COMPLETED · sponsor: **Knight Therapeutics (USA) Inc** · enrollment: 55 (actual)

## Conditions studied

- Mucocutaneous Leishmaniasis

## Interventions

- **DRUG:** Miltefosine

## Key facts

- **NCT ID:** NCT02431429
- **Lead sponsor:** Knight Therapeutics (USA) Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2018-02-23
- **Final completion:** 2019-03-01
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2019-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02431429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02431429, "Spermiogram Assessment in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02431429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*